Ovid Therapeutics INC 8-K filings

Ovid Therapeutics reported Q2 2026 business updates and financial results, highlighting progress in its OV4071 and OV329 programs, a strategic soticlestat transaction, and strengthened leadership.

Ovid Therapeutics announces the appointment of Charles Carter as Chief Financial Officer and the departure of Jeffrey Rona, effective July 6, 2026.

Ovid Therapeutics Inc. announced the results of its annual meeting of stockholders held on June 10, 2026, including the election of a director and advisory approval of executive compensation.

Ovid Therapeutics Inc. announced the appointment of Dr. Anna Greka to its Board of Directors, effective June 15, 2026, expanding the board to seven members.

Ovid Therapeutics announced first quarter 2026 business updates and financial results, highlighting progress in its OV329 and OV4071 programs and a strengthened balance sheet.

Ovid Therapeutics Inc. announced the expiration of its Series A Warrants, resulting in the exercise of most warrants and raising approximately $53.9 million in gross proceeds.

Ovid Therapeutics announced positive Phase 1 results for its KCC2 direct activator, OV350, supporting the advancement of its oral KCC2 portfolio.

Ovid Therapeutics Inc. stockholders approved an increase in authorized common stock, conversion of preferred stock and warrants, and issuance of securities to its CEO at a special meeting.

Ovid Therapeutics announced a leadership transition with Meg Alexander appointed CEO, positive Phase 1 results for OV329, progress in its KCC2 portfolio, and a private placement extending its cash runway.

Ovid Therapeutics announced a private placement expected to raise up to $175.1 million and positive Phase 1 topline results for its next-generation epilepsy drug candidate, OV329.

Ovid Therapeutics Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share, closing the matter.

Ovid Therapeutics reports Q2 2025 financial results, advances its neuroscience pipeline, and secures $7.0 million from ganaxolone royalty monetization, while addressing Nasdaq listing compliance.

Ovid Therapeutics Inc. announced that its stockholders approved all proposals at the Annual Meeting, including the election of two directors, advisory approval of executive compensation, ratification of KPMG LLP as auditor, and authorization for a reverse stock split.

Ovid Therapeutics Inc. announced the sale of its future ganaxolone royalty obligations to Immedica Pharma AB for $7.0 million in cash, providing non-dilutive funding and transferring intellectual property costs.

Ovid Therapeutics reports advancements in its clinical pipeline, including progress in Phase 1 studies for OV329 and OV350, along with a cash runway extending into the second half of 2026.

Ovid Therapeutics sets the date for its 2025 Annual Meeting of Stockholders as July 9, 2025, and outlines deadlines for stockholder proposals and director nominations.

Ovid Therapeutics announces business updates, Q4 and full year 2024 financial results, and key leadership appointments as it advances its clinical pipeline.

Ovid Therapeutics expands its Board of Directors from five to six members, appointing Stelios Papadopoulos as a Class I director effective March 1, 2025.

Ovid Therapeutics received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement for continued listing.

Ovid Therapeutics reported its third quarter 2024 financial results, provided a business update, and announced a strategic pause in a Phase 2 study.

Ovid Therapeutics has appointed Margaret Alexander as President and Chief Operating Officer, effective September 9, 2024, with a new employment agreement including a $500,000 base salary and stock options.

Ovid Therapeutics reported its second quarter 2024 financial results, appointed a new Chief Development Officer, and streamlined operations to focus on key clinical programs.

Ovid Therapeutics has announced the departure of its General Counsel, Thomas Perone, and a subsequent consulting agreement to ensure a smooth transition of duties.

Ovid Therapeutics and Graviton Bioscience reported positive topline results from a Phase 1 trial of OV888/GV101 capsule, a potential first-in-class therapy for cerebral cavernous malformations (CCM).

Ovid Therapeutics will reduce its workforce by 43% to prioritize programs and extend its cash runway, incurring a one-time charge of approximately $4.0 million.

Ovid Therapeutics reports on Takeda's Phase 3 study results for soticlestat, which showed mixed outcomes with one study narrowly missing its primary endpoint while the other missed it entirely, but both showing positive secondary results and a favorable safety profile.

Ovid Therapeutics held its annual meeting on June 6, 2024, where stockholders elected directors, approved executive compensation, and ratified the company's auditor.

Ovid Therapeutics reported its first quarter 2024 financial results and provided updates on its clinical pipeline, including progress on soticlestat, OV888, and OV329.

Ovid Therapeutics reports progress in clinical trials, anticipates key milestones, and provides financial results for 2023, highlighting a cash runway into the first half of 2026.